Bluebird Confident Beti-Cel Will Fare Better In US Than Europe

 
• By Alaric DeArment

The company built on its case for FDA approval with new beta-thalassemia data at ASH, but investor jitters linger after the pullout of Zynteglo from Europe amid reimbursement woes for the gene therapy.

Beta thalassemia blood sample - Image
bluebird bio presented data for beti-cel in beta thalassemia at ASH • Source: Shutterstock

More from Gene Therapies

More from Advanced Therapies